The clinical significance of HPV-16/18 E6 oncoprotein expression in non-small cell lung cancer (NSCLC) is not fully known. A study was undertaken to investigate the association between expression of human papillomavirus 16/18 E6 oncoprotein and survival in patients with stage I NSCLC. We analyzed a series of 217 patients with stage I NSCLC for the presence of HPV-16/18 E6 oncoprotein by immunohistochemistry. HPV-16 E6 onco-protein was expressed in 49 (22.6%) patients and HPV-18 E6 oncoprotein was expressed in 31 (14.3%) patients. Statistical analysis revealed that the prevalence of expression of HPV-16 and HPV-18 E6 oncoproteins was significantly high in female patients, nonsmokers and patients with adenocarcinoma. The adjusted odds ratio for expression of HPV-16 E6 oncoprotein in female patients was 2.275 [95% confidence interval (CI), 0.999-5.179] and that in patients with adenocarcinoma was 2.320 (95% CI, 1.029-5.232). These ratios were significantly higher than those in male patients and patients with squamous cell carcinoma. Interestingly, we found that the 17 patients who expressed HPV-16 and HPV-18 E6 oncoprotein had a higher 5-year cumulate survival rate (72.2%) than the 154 patients who did not express both oncoproteins (48.3%); the difference was significant (p=0.055). Expression of HPV-16/18 E6 oncoprotein in stage I NSCLC may play an important role in female adenocarcinoma patients and survival benefits in patients who expressed HPV-16 and HPV-18 E6 oncoprotein.
Introduction
Lung cancer is the most common cause of cancer-related deaths in the world, causing more than one million deaths worldwide each year (1) . Pathological stage I non-small cell lung cancer (NSCLC) represents the fastest growing segment of patients with lung cancer because of the frequent use of high-resolution CT scan for screening (2) . Although the prognosis is best for patients with pathological stage I NSCLC, the 5-year survival rate among these patients is only 57-67% (3). Histopathologic findings alone are insufficient to predict disease progression and clinical outcome. Factors that predict poor outcome in patients with stage I disease include the presence of the K-ras oncogene (4), a high ratio of type IV collagenases to E-cadherin (5), a low level of bcl-2 protein (6) , and the loss of blood-group antigen A (7). However, none of these factors can be clinically detected, and no medical strategy has been developed to target these biomarkers. Thus, a multifactorial process depending on demographic, clinical, and biological characteristics should be sought to further improve survival in patients with pathological stage I NSCLC.
In our preliminary study, we found that human papillomavirus (HPV) infection is associated with lung cancer development in nonsmoking female patients (8) . In contrast to studies that have demonstrated absence or low frequency of HPV infection in lung tumors (9-11), higher frequencies of HPV infection (25.6-78 .3%) in the same malignancy have been observed in Japan, Northern Iran, Finland and Norway (12) (13) (14) (15) . The association between HPV infection and lung cancer therefore has been suggested to be geographically-and race-dependent (8) .
E6 proteins encoded by HPV bind to the host cellular tumor suppressor protein, p53, and induce its degradation through the ubiquitin pathway (16, 17) . Thus, inactivation of p53 by HPV E6 is considered to play a crucial role in human carcinogenesis. Kinshoshita et al reported that HPV-18 E6 mRNA was detected in squamous cell carcinoma (SCC) (1/10, 10%) and adenocarcinoma of the lung (2/22, 9%), while no 
Materials and methods
Study subjects. From January 2000 to December 2006, a total of 217 consecutive patients underwent surgical treatment for NSCLC at the China Medical University Hospital, Taichung, and at the Taichung Veterans General Hospital. Patients who had preoperative chemotherapy or radiotherapy were excluded from this study. Written informed consent to use paraffinembedded tissues and information regarding sociodemographic characteristics, as approved by the Institutional Review Board at the above two hospitals, was obtained from each patient before surgery. All of the available paraffin blocks were reviewed by a thoracic pathologist.
The study population consisted of 148 men and 69 women (mean age, 65.2 years; range, 37-83 years). Surgical treatment for NSCLC comprised pneumonectomy (n=3; 1.4%), bilobectomy (n=12; 5.5%), lobectomy (n=180; 83.0%) and wedge resection (n=22; 10.1%). All procedures included sampling of hilar and mediastinal lymph nodes, and pathology of all specimens confirmed stage I (T1-2N0M0) in all patients (3). Histological classification and grade were assessed by light microscopy according to WHO criteria (21) . Clinical data including sex, age (≤65 years vs. >65 years), smoking habit, histopathology (SCC vs. adenocarcinoma), tumor stage by TNM (T1 versus T2) and tumor differentiation were collected from patient charts and are shown in Table I .
Post-operative follow-up was scheduled at 1, 2, and every 3 months during the first 2 years after surgery, and every 6 months thereafter, or more frequently if needed. The median duration of follow-up after a curative resection was 4.7 years.
Immunohistochemistry. All sections of formalin fixed and paraffin-embedded specimens were deparaffinized in xylene, rehydrated through serial dilutions of alcohol, and washed with PBS (pH 7.2). For HPV-16/18 E6 detection, sections were heated in a microwave oven twice for 5 min in citrate buffer (pH 6.0), and then incubated with polyclonal antibodies raised against HPV-16/18 E6 (Santa Cruz, CA, USA and Chemicon International, Inc., CA, USA) for 90 min at 25˚C. The conventional streptavidin peroxidase method (Dako, LSAB kit K675, Copenhagen, Denmark) was performed to develop signals and the cells were counterstained with hematoxylin. The intensities of signals were evaluated independently by three observers. Negative immunostaining was defined as 0-10% positive nuclei; positive immunostaining was defined as >10% positive nuclei. The cervical cancer tumor tissues with HPV-16/18 were used as positive control for HPV16/18 E6. The antibody dilution buffer used to replace antibodies served as the negative control.
Statistical analysis. The significance of gender, age, histopathology, tumor stage by TNM, and tumor differentiation for the expression of E6 oncoprotein of HPV-16/18 was analyzed by the Chi-square test. Multiple logistic regression analysis was used to assess which variables were important for expression of E6 oncoprotein of HPV-16/18 and which factors might act as risk factors. Survival plots were generated using the Kaplan-Meier method and differences between patient groups were determined by the log-rank test. All reported p-values are two-sided; p<0.05 was considered significant.
Results
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had a higher OR (95% CI, 1.029-5.232; p<0.05) than patients with SCC (Table III) . Univariate analysis of survival showed that female patients and age ≤65 years were prognostic factors (Table V) . Although patients with HPV-16 or -18 E6 oncoprotein expression had better survival outcomes than those lacking expression of either oncoprotein, there was no significant difference. Interestingly, a small group of 17 patients with HPV-16 and -18 E6 oncoprotein expression had better survival outcomes than the 154 patients lacking expression of both oncoproteins (Fig. 2) ; the difference was significant (p=0.055).
Discussion
This study used immunohistochemistry to investigate the clinicopathological role of HPV-16/18 E6 oncoprotein expression in patients with pathological stage I NSCLC. The frequency of HPV-16 and -18 E6 oncoprotein expression was 22.6 and 14.3%, respectively, which was less than that of HPV-16 (34.8%, 50/141) and that of HPV-18 (40.4%, 58/141) resulting from hybridization in our previous study (8) . For prognostic biomarkers with clinical potential, the approach involving HPV tumor status is strongly dependent on the performance of the assay for HPV detection as well as the definition of a positive test (22) . Viral oncogene expression is considered the gold standard for establishing the HPV etiology of a tumor in young women with a high-risk of cervical HPV infection and normal cervical cytology (23) . Generally, the detection rates of HPV in lung cancers show wide variations, recording ~2739 cases described a detection rate of 22.16% from various studies (20, 24, 25) . Our current study represents the first report of HPV-16/18 E6 oncoprotein expression in patients with pathological stage I NSCLC in Taiwan.
Similar to other studies, our immunohistochemical results demonstrated that HPV-16/18 E6 oncoprotein expression affects the demographics, clinical presentation, and histopathology of lung cancers patients. Patients with HPV-positive head and neck squamous cell carcinoma (HNSCC) tend to be younger, nonsmokers, and nondrinkers; in addition, their tumors tend to arise largely from the lingual and palatine tonsils in the oropharynx (26) . Histopatholocally, HPV-positive HNSCC tends to have a poorly differentiated and frequently basaloid histology (26, 27) . The results from our previous study are similar to the results obtained from the current study and 
indicate that there is a significant association between HPV-16/18 infection and nonsmoking females and patients with adenocarcinoma of the lung (8) . The results from both of our studies contrast with those in other studies which show that HPV-16/18 is more prevalent in patients with lung SCC than in patients with lung adenocarncinoma (13, 15) . The role HPV-16/18 infection plays in the development of lung adenocarcinoma needs to be investigated further (8) . Furthermore, multiple logistic regression analyses showed that females, nonsmokers and patients with adenocarcinoma had significantly higher odds of expressing HPV-16 E6 oncoprotein. After adjusting for sex, age, smoking habit, tumor stage and pathology, females (OR, 2.275) and patients adenocarcinoma (OR, 2.320) still had significantly higher ORs. For HPV-18 E6 expression, there were no significant variables after adjusting for sex, age, smoking habit, tumor stage and pathology.
To our knowledge, no studies demonstrating the clinical outcome for HPV-16/18 E6 oncoprotein expression in pathological stage I NSCLC patients have been published. The results from this study revealed that patients with HPV-16 and -18 E6 oncoprotein expression had significantly higher 5-year cumulate survival rates than patients lacking expression of both proteins. Similarly, most previous studies on HNSCC have demonstrated that patients with HPV infection have a better prognosis than HPV-negative patients (27) (28) (29) (30) .
Ragin and Taioli conducted a meta-analysis on the overall relationship between HPV infection and overall survival and disease-free survival in HNSCC, and found that patients with HPV-positive HNSCC had a lower risk of dying, and a lower risk of recurrence than HPV-negative HNSCC patients (31) . The reason for the improved survival is still unclear; however, improved radiation responsiveness, immune surveillance to viral antigens, and the absence of field cancerization in nonsmokers have been postulated (26) . In addition, HPVpositive tumors tend to have a wild-type p53 that is functionally inactivated by E6 oncoprotein. Conversely, HPV-negative tumors usually have a specific p53 mutation that can be induced by smoking (26) . In our recent study, we investigated the p53 mutation rate in 483 lung cancer patients and found that the frequency of mutation was higher in male smokers and lowest in female nonsmokers (data not shown). Collectively, E6-related degradation of p53 in HPV-positive cancers may be functionally inequivalent to HPV-negative p53 mutations (32, 33) ; and therefore, HPV-positive tumors may have an intact apoptotic response to radiation and chemotherapy (34) . Furthermore, a previous study has shown that infection with potentially oncogenic HPV types could co-operate with K-ras gene activation in the progression of the disease, since K-ras activation by point mutations seems to be a late event in lung carcinogenesis (35) .
Our recent study regarding p53 mutation and immunostaining results from female lung cancer patients lead us to consider the possibility that HPV infection may be associated with lung tumorigenesis through an HPV E6-dependent p53 degradation pathway, similar to the tumorigenesis of HPVassociated cervical cancer (36) . Plausibly, HPV-16/18 infection may partly play a role in lung tumorigenesis in nonsmoking Taiwanese women. In consideration of poorer prognosis of HPV-16-and HPV-18-negative patients with pathological stage I NSCLC, subsequent adjuvant therapy is warranted.
